CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Peginterferon alfa-2adrug
Likely dose
Peginterferon alfa-2a 180 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02791269
NCT02791269Phase 4Completed
CompareCT.gov

Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B

Hoffmann-La Roche·interventional·Posted Jun 6, 2016·Updated Feb 6, 2017

In Brief

A Phase 4 clinical trial evaluating Peginterferon alfa-2a for Hepatitis B, Chronic. Completed, enrolled 24 participants across 6 sites.

Detailed Summary

This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48 weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free follow-up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesNew Zealand
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 6, 2016
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.1 years ago

Interventions

Peginterferon alfa-2adrug

180 mcg SC injection QW for 48 weeks.